Overview
Quick answer
Medicare does not fund "blood tests" as a category. It funds specific pathology items on the Medicare Benefits Schedule (MBS) when a treating practitioner decides the service is necessary.
Health screening is excluded by default. A health screening service is a test that is not reasonably required for the management of the patient's medical condition. The Minister has directed that benefits can still be paid for a test on a symptomless patient by that patient's own medical practitioner, for tests considered reasonably necessary given age, physical condition, and personal or family history. The same note says a routine check-up "should not necessarily be accompanied by an extensive battery of diagnostic investigations."
That is why a GP can rebate a focused check-up set, and why a 40-marker preventative panel is usually private. The difference is structural, not a paperwork trick.
Overview
Key takeaways
Screening is excluded unless a ministerial direction applies. Feeling well is not, by itself, a reason for an MBS rebate.
A check-up can still fund indicated tests ordered by your own GP. The MBS example is a lipid estimation where there is a family history of lipid disorder, not a standing invitation to order everything.
An MBS item is not a marker. Five or more tests from the 66500 chemical list bill as one item (66512). A long printout can still be a short claim.
Episode coning limits the Medicare benefit on a GP request for a non-hospital patient to the equivalent of the three highest schedule fees. Specialists and hospital inpatients are not coned the same way.
Vitamin D, diagnostic HbA1c, B12, and free T4 or T3 have extra rules. ApoB, Lp(a), and AMH are classified as non-MBS-rebatable immunoassays.
The schedule fee is not your bill. The usual out-of-hospital Medicare benefit is 85% of that fee. Bulk billing means the lab accepts that benefit as full payment.
Hemexa membership panels are private. They are not a method for billing a comprehensive preventative panel to Medicare.
The rule
What Medicare actually pays for
The MBS is a list of items, fees, and rules. Category 6 is pathology. A rebate is payable when the treating practitioner determines that the pathology service is necessary, and when the request and the item descriptor both fit.
GN.13.33 is the note that answers the search query. Unless the Minister otherwise directs, Medicare benefits are not payable for health screening services. The note defines a health screening service as a medical examination or test that is not reasonably required for the management of the medical condition of the patient.
The excluded list includes multiphasic health screening, fitness testing for a training or weight-reduction program, and several compulsory licence or admission examinations. A wellness panel ordered because someone wants a baseline, with no clinical reason attached, sits in that excluded class.
Necessity is a clinical decision
PN.1.1 states the basic requirement: the treating practitioner must determine that the pathology service is necessary. The collection centre cannot invent that determination, and a membership form cannot either.
The request has to exist
A pathology service is provided on a request from a treating practitioner. That is why every reputable Australian pathway, Medicare or private, still goes through a registered GP or specialist.
The item descriptor is the second gate
Even when a GP wants a test, the item wording can still refuse the rebate. Vitamin D (66833) is the clearest example: the indication has to be one of the listed clinical situations, not "tired" or "winter."
The Department of Health page "What Medicare covers" says the MBS covers pathology tests to screen for, diagnose, or monitor disease. That sentence is true and incomplete. The screening that is covered is the screening the Minister has directed, plus tests that are reasonably required to manage a condition, not an open preventative catalogue.
The exception
What a check-up can still fund
The same GN.13.33 note then lists the categories of health screening the Minister has directed should be paid. The one that matters for a blood-test search is paragraph (a).
Benefits are payable for a medical examination or test on a symptomless patient by that patient's own medical practitioner, in the course of normal medical practice, so the patient can receive any medical advice or treatment necessary to maintain their state of health. Benefits are payable for the attendance and for tests considered reasonably necessary according to the patient's individual circumstances, such as age, physical condition, and past personal and family history.
The worked examples in the note are a cervical screening test, and "blood lipid estimation where a person has a family history of lipid disorder." The next sentence is the one most coverage pages skip: "However, such routine check-up should not necessarily be accompanied by an extensive battery of diagnostic investigations."
Own medical practitioner
The direction is for a test requested by the patient's own doctor in normal practice. It is not a standing rebate for a one-off wellness clinic list, and it is not a self-referral to a 40-marker catalogue.
Reasonably necessary, not exhaustive
Age, history, and physical condition can justify a focused set. They do not convert a check-up into a funded longevity panel. The lipid example is one indicated test, not "and also insulin, ApoB, AMH, and a full hormone stack."
The battery limit is the product-shaped sentence
Medicare can fund a check-up blood test. It is not required to fund an extensive battery. That is the legal shape of the gap a private preventative panel fills, and it is why this page can carry a membership CTA without pretending the rebate was supposed to cover the same thing.
Whether a given request is "reasonably necessary" is a question for the requesting practitioner and, if audited, for the rules as they apply to that record. This page can quote the note. It cannot certify a specific form.
Items, not markers
How an MBS item works
People search "what blood tests does Medicare cover" and expect a marker list. The MBS pays items. One item can print as a dozen results, and two markers that look related can sit on different items with different rules.
The chemical group is the cleanest illustration. Item 66500 is quantitation of one test from a long list: electrolytes, liver enzymes, glucose, creatinine, urea, C-reactive protein, total cholesterol, triglycerides, magnesium, and others. Two of those tests bill as 66503 (schedule fee $11.65). Three bill as 66506 ($13.65). Four bill as 66509 ($15.65). Five or more bill as 66512 ($17.70).
A standard EUC plus liver panel plus glucose plus CRP is therefore often one item, not eight. That is why a long Australian printout can still be a short Medicare claim, and why "Medicare only pays for three tests" is the wrong picture.
Schedule fee versus 85% benefit
Each item publishes a schedule fee and an 85% out-of-hospital benefit. For item 65070 (full blood count) the fee is $17.80 and the 85% benefit is $15.15, from 1 July 2026. The fee is what the schedule lists. It is not an out-of-pocket quote.
Bulk billing is a lab decision
If the approved pathology authority bulk bills, it accepts the Medicare benefit as full payment and you pay nothing for that item. If it does not, the gap is the difference between what the lab charges and what Medicare pays. Ask the collection site before you sit down.
Indexation is uneven
From 1 July 2026, annual indexation applied to pathology Groups P1, P4, P5, P6, P8, and P12. Group P2 chemical items, which include lipids, liver and kidney panels, TSH, iron studies, HbA1c, B12, and vitamin D, were not in that list. Their fees on the live lookup still show older schedule-fee dates.
The payment cap
Episode coning on a GP request
The Department of Health public page says that if a GP requests more than three tests on the same day, Medicare will only pay for the three most expensive tests. That is the consumer shorthand. The operative notes are PN.5.1 and PR.6.1, describing Rule 18, the episode cone.
The cone applies to pathology services requested by a general practitioner for a non-hospitalised patient. It does not apply to hospital inpatients, and it does not apply to services ordered by specialists.
When more than three items are requested in one patient episode, Medicare benefits are equivalent to the sum of the benefits for the three items with the highest schedule fees. The two highest items are paid as themselves. Everything else is treated as one service, paid at the third-highest schedule fee. Items with the same fee are ranked by item number.
A patient episode is broader than one form
PN.0.5 defines a patient episode as the pathology services whose need was determined on the same day, even if specimens are collected over several days, and even if more than one request is written. Tests on the same specimen within 14 days stay in the same episode.
Items, not printed markers
Coning counts claimable items. A 66512 chemical panel is one item even if the report lists sodium, potassium, creatinine, eGFR, ALT, AST, GGT, bilirubin, and glucose. Adding iron studies (66596) and TSH (66716) and an FBC (65070) is how a request becomes four items.
The lab may still run the coned tests
Australian Pathology's 2020 update on the cone describes the usual practice: tests outside the three reimbursed items are still performed, and the cost is borne by the pathology provider. You can receive a result Medicare did not separately rebate. That is not the same as Medicare funding a preventative catalogue.
Groups P10 to P13 (episode initiation, specimen referred, bulk-billing items) are excluded from the count, as are listed exemptions in Rule 18. The cone is a payment cap on a GP outpatient episode, not a clinical protocol.
Common items
Tests a check-up often funds
| Test | Item | Schedule fee | 85% benefit | Typical rule |
|---|---|---|---|---|
| Full blood count (FBC / FBE) | 65070 | $17.80 | $15.15 | No 12-month frequency cap on the item. Indexed from 1 July 2026. |
| Five or more tests from the 66500 chemical list (typical EUC, LFT, glucose, CRP grouping) | 66512 | $17.70 | $15.05 | One item for five or more 66500 analytes. Two, three, or four tests use 66503, 66506, or 66509. |
| One test from the 66500 list (for example glucose, or total cholesterol alone) | 66500 | $9.70 | $8.25 | Each extra analyte on that list steps up the 66503 to 66512 ladder. |
| HDL cholesterol | 66536 | $11.05 | $9.40 | Separate from the 66500 lipid analytes. Calculated LDL-C has no extra item. |
| TSH | 66716 | $25.05 | $21.30 | First-line thyroid item. Free T4 and free T3 sit on 66719 with extra conditions. |
| Iron studies (iron, transferrin or TIBC, and ferritin) | 66596 | $32.55 | $27.70 | The grouped iron studies item. Ferritin alone is 66593 ($18.00) if not requested as part of iron studies. |
| One listed hormone or binding protein (oestradiol, FSH, LH, testosterone, SHBG, insulin, and others) | 66695 | $30.50 | $25.95 | One assay. Extra assays on the same request use the related P2 items. Clinical indication still applies. |
A full blood count, a chemical panel, TSH, and iron studies are the set most check-up requests actually resemble. They are still indicated tests, not a funded longevity catalogue.
These fees were read from MBS Online on 15 August 2026. They change when the schedule is amended. They are not a promise that your collection site will bulk bill, and they are not a private price list.
Restricted items
Tests with extra Medicare rules
Some items are payable only when the request matches a tighter descriptor. That is the usual reason a "standard check-up" silently drops vitamin D, a full thyroid panel, or a second HbA1c.
Vitamin D, item 66833, schedule fee $30.05
25-hydroxyvitamin D is payable for a listed set of situations: osteoporosis or osteomalacia; raised ALP with otherwise normal liver tests; parathyroid or calcium or phosphate disorders; malabsorption; deeply pigmented skin or chronic severe lack of sun; medicines known to lower 25OH-D; chronic renal failure or transplant; and specified infant and sibling criteria. Tiredness, hair shedding, and brain fog are not on that list.
Vitamin B12, item 66838, schedule fee $23.60
Quantification of total B12 and/or holotranscobalamin is payable not more than once in 11 months. Item 66842 covers a broader marker set, including methylmalonic acid or homocysteine, when symptoms persist, a prior result was inconclusive, or a listed risk factor applies. The 1 July 2025 amendment is what created that pathway.
HbA1c diagnosis versus monitoring
Item 66841 ($16.80) is a diagnostic HbA1c in an asymptomatic patient at high risk, and is subject to Rule 25. Item 66551 ($16.80) is for established diabetes and is payable at most four times in 12 months, including point-of-care items 73812 and 73826. A well adult who wants a metabolic baseline is not automatically on either item.
Free T4 and free T3, item 66719, schedule fee $34.80
The item includes TSH plus free T4 and/or free T3 only if TSH is outside the method reference range, or the request records monitoring of known thyroid disease, investigation of sick euthyroid syndrome in an admitted patient, dementia or psychiatric illness, amenorrhoea or infertility, suspected pituitary dysfunction, or drugs that interfere with thyroid hormone metabolism. A screening TSH is 66716. A "full thyroid panel" is not the default rebate.
The vitamin D, vitamin B12, and HbA1c guides walk the clinical reading. This page only covers the rebate gate.
Outside the rebate
Tests Medicare usually does not rebate
A test can be a routine, NATA-accredited Australian assay and still sit outside the rebate. RCPA classifies some immunoassays as non-MBS-rebatable. Others are on the schedule but are not intended as asymptomatic screens.
ApoB and lipoprotein(a)
Both are standard assays. RCPA classifies the immunoassays as non-MBS-rebatable. MSAC application 1512 for ApoB in high-risk cardiovascular assessment was not supported. Typical private add-on prices already published on Hemexa's marker guides are about $30 to $80 for ApoB and $40 to $90 for Lp(a).
AMH
The RCPA Manual classifies anti-Mullerian hormone as non-MBS-rebatable. Australian labs bill it as a private add-on. It is not a menopause test, and it is not a default PCOS add-on.
Fasting insulin as a screen
Insulin is listed on item 66695, so a clinically indicated assay can be rebated. AJGP 2021 and the 2023 PCOS guideline both advise against insulin assays as routine screening for prediabetes, diabetes, or PCOS workups. A preventative insulin request is often private for that reason, not because the molecule is missing from the schedule.
hs-CRP as a cardiovascular add-on
Standard CRP is one of the 66500 chemical tests, so it can sit inside a rebated 66512 panel when the GP includes it. The high-sensitivity assay used for low-grade cardiovascular risk is the test preventative panels mean by hs-CRP, and that use is often a private add-on in an asymptomatic adult.
See the ApoB and high cholesterol guides for why a standard lipid panel and a particle count are different tests, and different bills.
The useful skill
How to read a Medicare pathology invoice
Competing Australian explainers either publish an item table with the wrong numbers, or tell you a standard check-up includes vitamin D. The useful skill is reading the two documents you actually receive: the request, and the invoice or bulk-bill statement.
Clinical notes on the request
Restricted items are payable when the request records the matching indication. "Check-up" is not a vitamin D indication. "Family history of lipid disorder" is the GN.13.33 example for a lipid estimation. If a rebate is refused, the notes are the first place to look, not the collection queue.
Item numbers, not marker names
The invoice, if you see one, lists MBS items. "LFT" on the request may appear as 66512. "Cholesterol" may be two 66500-list tests (66503) plus HDL as 66536. If the numbers do not match the names you expected, the ladder above is why.
Benefit versus gap
A bulk-billed episode shows a Medicare benefit and a zero gap. A privately billed episode shows the lab fee, the 85% benefit, and a gap. The schedule fee on MBS Online is the reference point, not a quote the lab is required to charge.
Results you received, items that were coned
A long report does not prove Medicare paid for every line. Under the cone, the lab may still issue results for items that were not separately rebated. The report is a clinical document. The claim is a payment document.
Limits
What this page cannot decide
Whether your form meets GN.13.33
The note sets conditions. Whether a given attendance and a given set of tests were reasonably necessary is not a question a webpage can answer, and it is not a question Hemexa can certify for a reader it has not assessed.
What your collection site will charge today
Bulk billing is common in Australian pathology and is not guaranteed. Fees and gap policies change by provider and by site. Ask before collection.
A workaround that turns a private panel into a rebate
Splitting a preventative catalogue across several GP forms written on the same day can still be one patient episode. The cone and the screening note are not defeated by extra paper.
Private pathways
How Australians get a broader panel
If the question is a clinically indicated check-up, start with your GP. If the question is a baseline that includes markers the MBS does not rebate for a well adult, the path is private.
| Approach | Best for | Typical cost | What it includes |
|---|---|---|---|
| GP-ordered, Medicare-funded | Indicated tests your own GP judges reasonably necessary | Bulk-billed or a gap on the 85% benefit | The items that fit the request and the descriptors, then coned if more than three GP items |
| GP-ordered private add-ons | ApoB, Lp(a), AMH, or a restricted item that does not meet its descriptor | The lab's private fee for those assays. Published Hemexa ranges: ApoB about $30 to $80, Lp(a) about $40 to $90, iron studies about $62 to $75 when billed privately | Whatever the GP writes as private. Medicare does not convert those lines into 66512. |
| Pay-per-panel preventative service | A one-off wider panel without a membership | Often $150 to $800+ depending on marker count, already published on Hemexa's preventative guide | A GP-reviewed request and a private invoice. Not a Medicare check-up by another name. |
| Hemexa membership | An annual baseline plus an included six-month retest, with trends rather than a single PDF | AU$1,199 per year | A GP-reviewed request, Healius Pathology collection, and 76–80 signature markers on the annual panel. Private. Not billed to Medicare as a comprehensive preventative item. |
A membership does not replace your GP, and it does not stop your GP ordering indicated tests on Medicare in the usual way. The two pathways answer different questions. The preventative blood test guide covers what to put on that wider panel once payment is settled.
FAQ
Frequently asked questions
- Does Medicare cover blood tests in Australia?
- Yes, when the test is an MBS pathology item and the treating practitioner determines it is necessary. Medicare does not cover blood tests as an open category. Health screening is excluded unless a ministerial direction applies.
- Does Medicare cover a full body blood test or a 40-marker panel?
- Not as a preventative catalogue. GN.13.33 allows indicated tests on a symptomless patient by their own practitioner, and says a routine check-up should not necessarily be accompanied by an extensive battery of diagnostic investigations. Broad preventative panels are typically private.
- If my GP requests more than three tests, does Medicare only pay for three?
- For a GP request on a non-hospital patient, episode coning (Rule 18, notes PN.5.1 and PR.6.1) limits the benefit to the equivalent of the three highest schedule fees. The two highest items are paid as themselves; remaining items are treated as one service at the third-highest fee. One item can still be many printed markers. Specialists and hospital inpatients are not coned this way.
- Is vitamin D covered by Medicare?
- Only when the request matches item 66833. The listed reasons include osteoporosis or osteomalacia, certain bone-mineral disorders, malabsorption, deeply pigmented skin or chronic severe lack of sun, specified medicines, chronic kidney disease or transplant, and defined infant and sibling criteria. A routine check-up, tiredness, or hair loss is not a listed reason.
- Is HbA1c covered by Medicare?
- Item 66841 funds a diagnostic HbA1c in an asymptomatic high-risk patient and is subject to Rule 25. Item 66551 funds monitoring in established diabetes, at most four times in 12 months. A preventative metabolic panel that includes HbA1c without those settings is often private.
- Are ApoB and Lp(a) covered by Medicare?
- RCPA classifies both immunoassays as non-MBS-rebatable. A GP can still request them as private add-ons. Typical standalone prices already published on Hemexa's marker guides are about $30 to $80 for ApoB and $40 to $90 for Lp(a).
- What is the difference between the schedule fee and what I pay?
- The schedule fee is the MBS list price for the item. The usual out-of-hospital Medicare benefit is 85% of that fee. If the lab bulk bills, you pay nothing for that item. If it does not, you pay the gap. The schedule fee is not an out-of-pocket quote.
- Can I use Medicare and a Hemexa membership for the same blood draw?
- Hemexa membership panels are private. They are not billed to Medicare as a comprehensive preventative item. Your own GP can still order indicated tests on Medicare in the usual way. Do not assume a membership request is a Medicare request.
- Do I need a GP to get a Medicare-funded blood test?
- Yes. A treating practitioner has to determine that the service is necessary and make the request. A participating nurse practitioner can request a defined range of pathology items. There is no self-referral rebate for a wellness panel.
- How much does a preventative blood test cost if Medicare will not fund it?
- Pay-per-panel comprehensive tests are often $150 to $800+ depending on marker count. Membership platforms that include an annual baseline of 76–80 signature markers and a six-month retest start around AU$1,199 per year.
How Hemexa fits
How Hemexa can help
Hemexa exists for the panel Medicare is not required to fund: a structured baseline, a six-month retest, and a trend you can read beside the Healius reference interval. It is not a bulk-billing product and it does not replace indicated GP care.
A private baseline, stated as private
Membership includes the annual panel of 76–80 signature markers and an included six-month retest, coordinated on a GP-reviewed request, with collection through Healius Pathology. That panel is paid as membership, not claimed as an extensive MBS battery.
Markers the schedule leaves out of a check-up
ApoB, Lp(a), fasting insulin, hs-CRP, ferritin, B12, 25-OH vitamin D, and the hormone set sit on the 76–80 marker annual baseline. Some of those have MBS items with tight rules. Some have no rebate at all. The membership does not depend on either fact.
Your GP stays the indicated-care path
If you have symptoms, a family history that justifies a lipid estimation, or a condition that needs monitoring, that conversation belongs with your own practitioner and, where it fits, with Medicare. Hemexa organises preventative pathology and trends. It does not certify that a request meets GN.13.33, and it does not prescribe.
Sources
References
Medicare Benefits Schedule. Note GN.13.33, Health screening services. View source ↗
Medicare Benefits Schedule. Note PN.0.5, Patient episode. View source ↗
Medicare Benefits Schedule. Note PN.5.1, Episode cone. View source ↗
Medicare Benefits Schedule. Note PR.6.1, Episode cone (Rule 18). View source ↗
Australian Government Department of Health, Disability and Ageing. What Medicare covers. View source ↗